Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
ConclusionsOS after TACE with miriplatin was not superior to that after TACE with epirubicin; however, hepatic AEs were less frequent with miriplatin.Clinical Trial Registration: JapicCTI-080632.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Cancer & Oncology | Carcinoma | Children | Clinical Trials | Gastroenterology | Hepatocellular Carcinoma | Liver Cancer | Study | Toxicology